Share on

Europe Schizophrenia Drugs Market Research Report – Segmented By Therapeutic Class, Treatment & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 8018
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the Europe Schizophrenia Drugs Market was worth USD 2.06 billion in 2022 and estimated to be growing at a CAGR of 2.21%, to reach USD 2.30 billion by 2027.

Factors that are primarily encouraging the schizophrenia drugs market in the European region include the growing mental health disorder of the population. In the European region, governments spent an average of 23 per capita on mental health programs and services to promote mental health to their citizens. Furthermore, almost all countries in the European region had an integrated mental health policy or planned following international human rights instruments. These compose child and adolescent mental health plans in about 77.25% of their countries. In addition, almost all countries in Europe have separate legislation for mental health incorporated into the general health or disability law.

In addition, the increase in the number of patients receiving treatment and the growing demand for improved healthcare infrastructure is anticipated to drive the market. Furthermore, with the number of psychiatrists and mental health advocates, many hospitals are making arrangements to protect people against schizophrenia better. In addition, the increasing burden of mental diseases is helping the public and private healthcare companies cater to better products and adjunct therapies, fueling the growth of businesses in the segment. Hence, considering the abovementioned factors, the market is anticipated to grow steadily during the forecast period.

However, the increase in drug addiction, risk of dependence, lack of knowledge about the drugs and mental illnesses, and the expiration of patents on major factors hampering the growth of the European schizophrenia drugs market.

This research report on the European schizophrenia drugs market has been segmented and sub-segmented into the following categories.

By Therapeutic Class:

  • Second generation anti-psychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third generation anti-psychotics  
  • Others    

By Treatment:

  • Oral anti-psychotics       
  • Injectable anti-psychotics 

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Germany accounted for the largest share of the European market for schizophrenia drugs market in 2020 and is expected to continue this trend throughout the forecast period owing to the diversity of health facilities, large patient base, and well-developed health infrastructure.

The schizophrenia drugs market in the United Kingdom is anticipated to grow at a CAGR of 2.78% during the forecast period. This growth is supported by a significant portion of the population with mental health disorders, supportive reimbursement policies, availability of mental health personnel, government programs on mental illness, and the growing awareness of mental health. Mental Health First Aid England is a social organization that supports mental health problems with expert advice and training. 1 in 4 people face mental health problems each year and are responsible for 73 million lost workdays and cost 45.5 billion each year, according to 2019 statistics from the Ministry of Health. In addition, significant cases of mental health disorders in the UK Armed Forces account for a substantial share of the schizophrenia prevalence. According to MHFA, in 2018-2019, around 2.79% of UK armed forces personnel were screened for mental health issues. England's National Health Services (NHS) spends $ 7.25 million per year on mental health services for ex-servicemen, on top of the USD 12.74 billion in mental health spending for the general population. As a result, they create significant market growth in the country.

France is also anticipated to register a healthy growth rate as it has a world-class healthcare system that provides a stable platform for market growth. In addition, Switzerland, the Netherlands, Denmark, Norway, Ireland, Hungary, and Belgium are also projected to contribute significantly to the development of the European market during the forecast period.

KEY MARKET PLAYERS:

Companies such as Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer are a few of the notable companies operating in the European schizophrenia drugs market profiled in this report.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample